Have a tailored conversation with our expert, Dr. Yvette Stallwood, about your candidates’ specific needs
• Assessing the potential for immunogenicity, immunotoxicity and potency of your candidate and manage potential liabilities
• Generating materials for your in vitro and in preclinical studies
• Creating cell lines and processes with future
manufacturability, cost of goods and speed in mind
Learn more about
Early Candidate De-risking and Optimization
Head of Lonza Early Development Services and Head of Cambridge (UK) Site
Dr. Yvette Stallwood
Dr. Yvette Stallwood
Head of Lonza Early Development Services and Head of Cambridge (UK) Site
Yvette Stallwood completed her PhD at the University of Birmingham (UK) and has a background in Virology, Cell & Molecular Biology. She joined Lonza in 2007, initially leading the cell and molecular biology expression group in the Applied Protein Services department and is currently Head of Early Development Services and Head of Cambridge site.
The Early Development Services team are focussed on the development and provision of services to support the development of new biotherapeutic proteins and vaccines with a particular focus on immunogenicity, manufacturability and protein expression.
6 - 10 February 2023
Meet our experts
in Korea
De-risk and optimize your candidate early
in development for clinical success
Contact us
Avoid & mitigate risk of failure when developing your biotherapeutic. Discuss your early phase challenges related to your molecule and milestones with our experts
Our lead selection and protein optimization services help identify and mitigate manufacturing and immunosafety risks, can reduce attrition and improve developability of therapeutic proteins.
Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. This is the phase when you make key decisions that will have long-term scientific and business impact. However, the journey can be long, expensive, resource straining, and risky due to high attrition rates.
In this early phase it is critical to have access to experts that understand your development journey.
Your tailored conversation with our expert can include:
• Building, with our experts, your early de-risking and optimization strategy with in silico and in vitro manufacturability screening, protein engineering and humanization tools